ADVERTISEMENT

Dhanuka Agritech Targets 18% Revenue Growth, 20% Volume Surge In FY25

Dhanuka Agritech on Nov. 25 announced a strategic partnership with Germany’s Bayer AG for global expansion.

<div class="paragraphs"><p>Dhanuka Agritech has several products in the pipeline, including grape fungicide, paddy fungicide, and a paddy herbicide, which will be launched in the next 12 months. (Photo source: Company website)</p></div>
Dhanuka Agritech has several products in the pipeline, including grape fungicide, paddy fungicide, and a paddy herbicide, which will be launched in the next 12 months. (Photo source: Company website)

Dhanuka Agritech Ltd. is aiming to clock 18% growth in revenue and 20% increase in volume in fiscal 2025 on an aggregate basis amid new product launches and its recent deal with Germany’s Bayer AG.

The agrochem company, on Nov. 25, announced entering into a strategic partnership with Bayer AG to acquire international rights to the crop protection active ingredients— Iprovalicarb and Triadimenol. The company has also launched several new products in the current fiscal.

Sharing Dhanuka Agritech’s growth prospects with NDTV Profit, the company’s executive director Harsh Dhanuka said that the company is set to achieve revenue estimates for its three major products.

“For the financial year, on an aggregate, we are looking at a 16% to 18% value growth and close to 18% to 20% of volume growth,” he said.

Dhanuka said that in the current fiscal, the company has launched three new products – Purge, Lynamo, and MYCORe Super. “These three products have received great response from the market, and we have been achieving our revenue objective for all the three products in this year."

"Going forward, we have a few more products in the pipeline, including grape fungicide, paddy fungicide, and a paddy herbicide, which will be launched in the next 12 months,” the top executive said.

Talking about the deal with Bayer AG, Dhanuka said that the company will be focusing on renewing marketing efforts to revive the volumes for the products.

“For Bayer, definitely, it's part of the generic portfolio because they are not covered under patent any longer. And, they contribute less than 1% to their global revenue. So it is not part of their strategic portfolio. However, for Dhanuka, it will form an important part of our product portfolio, and we will be focussing on renewing marketing efforts to revive the volumes, which have been on a declining trend,” the executive director added.

In 2023, Bayer AG had seen a global revenue for Iprovalicarb and Triadimenol to the tune of Rs 200 crore, according to Dhanuka.

Shares of Dhanuka Agritech closed 1.26% lower at Rs 1,508 apiece on the NSE on Friday, compared to benchmark Nifty 50 settling at 24,131.1 points, up 0.91%.

OUR NEWSLETTERS
By signing up you agree to the Terms & Conditions of NDTV Profit